2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. Annals Of Internal Medicine 2022, 175: 1221-1229. PMID: 35939812, DOI: 10.7326/m21-4119.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyLong-term extension studyHCV reinfectionDrug useExtension studyAgonist therapySuccessful treatmentHepatitis C virus (HCV) reinfectionHepatitis C virus infectionBenefits of cureC virus infectionChronic HCV infectionRate of reinfectionUrine drug screeningOngoing drug useClinical trial sitesSubsidiary of MerckHCV infectionCohort studyVirus reinfectionDohme Corp.Treatment completionGenotype 1Virus infectionHigh riskHealth-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
Dalgard O, Litwin AH, Shibolet O, Grebely J, Nahass R, Altice FL, Conway B, Gane EJ, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber BA, Platt H, Puenpatom A. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal Of Addictive Diseases 2022, 41: 213-224. PMID: 35920743, DOI: 10.1080/10550887.2022.2088978.Peer-Reviewed Original ResearchConceptsElbasvir/grazoprevirHepatitis C virus infectionC virus infectionOpioid agonist therapyHealth-related qualityEnd of treatmentHCV infectionAgonist therapyVirus infectionChronic hepatitis C virus (HCV) infectionImproved health-related qualityMental component summary scoresTreatment week 4Placebo-controlled studyOpioid agonist treatmentMedical Outcomes StudyComponent summary scoresSF-36v2 scoresTreatment differencesImproved HRQOLViral eradicationActing antiviralsOpioid dependenceAgonist treatmentGeneral health
2021
Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study
Gutierrez JI, Dubov A, Altice FL, Vlahov D. Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. Military Medical Research 2021, 8: 32. PMID: 34006328, PMCID: PMC8132436, DOI: 10.1186/s40779-021-00323-6.Peer-Reviewed Original ResearchConceptsDaily tabletHuman immunodeficiency virus (HIV) infectionMilitary healthcare settingsImmunodeficiency virus infectionPre-exposure prophylaxisU.S. military menTelehealth visitsResultsA totalVirus infectionProvider typeUtility scoresPrEP programHealthcare settingsMental healthMilitary providersProphylaxisMenSexInjectionConjoint analysis studyMilitary menService deliverySocial media groupsMedia groupsMedications
2020
THU436 Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR
Dalgard O, Litwin A, Dore G, Shibolet O, Grebely J, Nahass R, Altice F, Conway B, Gane E, Luetkemeyer A, Peng C, Iser D, Gendrano I, Kelly M, Haber B, Platt H, Puenpatom A. THU436 Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR. Journal Of Hepatology 2020, 73: s356. DOI: 10.1016/s0168-8278(20)31208-3.Peer-Reviewed Original Research
2019
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2018
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. The Lancet Infectious Diseases 2018, 18: 1397-1409. PMID: 30385157, PMCID: PMC6280039, DOI: 10.1016/s1473-3099(18)30469-9.Peer-Reviewed Original ResearchConceptsHCV acquisition riskAcquisition riskHCV incidenceModerate heterogeneitySystematic reviewHepatitis C virus acquisitionHepatitis C virus infectionHIV acquisition riskRisk of HCVC virus infectionNewcastle-Ottawa ScaleRisk of biasRisk of HIVNational InstituteCommunity-recruited PWIDOutcomes of interestIncident infectionsCohort studyHIV acquisitionHIV transmissionHigh prevalenceVirus infectionRecent incarcerationExclusion criteriaHigh risk
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1
2013
Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia
Margolis B, Al-Darraji HA, Wickersham JA, Kamarulzaman A, Altice FL. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 1538-1544. PMID: 24200265, PMCID: PMC3913085, DOI: 10.5588/ijtld.13.0193.Peer-Reviewed Original ResearchConceptsLatent tuberculous infectionTuberculin skin testTB symptomsTuberculous infectionTwo-step tuberculin skin testPrevious incarcerationHuman immunodeficiency virus (HIV) infectionLower body mass indexReactive tuberculin skin testImmunodeficiency virus infectionBody mass indexRoutine screening procedureCross-sectional surveyCD4 statusRoutine tuberculosisTST reactivityTuberculosis symptomsActive tuberculosisLTBI prevalenceOnly significant correlateMass indexNortheastern MalaysiaSkin testVirus infectionHIVImplementing methadone maintenance treatment in prisons in Malaysia
Wickersham JA, Marcus R, Kamarulzaman A, Zahari MM, Altice FL. Implementing methadone maintenance treatment in prisons in Malaysia. Bulletin Of The World Health Organization 2013, 91: 124-129. PMID: 23554524, PMCID: PMC3605007, DOI: 10.2471/blt.12.109132.Peer-Reviewed Original ResearchConceptsDose of methadoneMMT programHIV infectionHuman immunodeficiency virus (HIV) infectionMethadone maintenance treatment programDaily oral doseImmunodeficiency virus infectionMethadone maintenance treatmentMaintenance treatment programHarm reduction strategiesMinistry of HealthAdequate dosingOral doseMaintenance treatmentMethadone treatmentStandard operating proceduresMMT clientsVirus infectionTreatment programMethadoneOngoing educationInfectionDosePhase 3Tuberculosis
2011
Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCombination antiretroviral therapyPublic health implicationsTreatment outcomesPoor HIV treatment outcomesHuman immunodeficiency virus (HIV) infectionImmunodeficiency syndrome prevalenceHIV treatment outcomesImmunodeficiency virus infectionHealth implicationsMental illness treatmentSubstance use disordersCase management servicesAntiretroviral therapySecondary preventionSyndrome prevalenceTransitional careImmunological outcomesCriminal justice populationsVirus infectionIllness treatmentUse disordersHIVMental illnessAlcohol useMedical insurance
2009
Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications
Gupta S, Altice FL. Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications. Journal Of Urban Health 2009, 86: 263-279. PMID: 19184447, PMCID: PMC2648882, DOI: 10.1007/s11524-008-9338-z.BooksConceptsChronic viral infectionsHepatitis B virus infectionB virus infectionReview of diagnosisHBV infectionViral infectionVirus infectionMedical careChronic HBV infectionChronic hepatitis BChronic medical conditionsComprehensive medical carePublic health burdenPublic health impactHigh-risk behaviorsPublic health implicationsProvision of vaccinationUS correctional facilitiesCorrectional settingsHBV vaccineHepatitis BViral hepatitisTreatment guidelinesChronic infectionChronic illness
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individuals
2004
Hepatitis C virus infection in United States correctional institutions
Altice F, Bruce R. Hepatitis C virus infection in United States correctional institutions. Current Hepatology Reports 2004, 3: 112-118. DOI: 10.1007/s11901-004-0018-5.Peer-Reviewed Original ResearchHepatitis C virus infectionC virus infectionInjection drug usersVirus infectionDrug usersRisk reduction interventionsCurable infectionEffective therapyHigh prevalenceCare approachHigh riskReduction interventionsMental illnessSexual partnersInfectionHealth carePublic healthCorrectional settingsSettingHCVIdeal settingHIVTherapyIllnessPrevalence
2003
Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis
Springer SA, Altice FL. Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis. Clinical Infectious Diseases 2003, 36: e162-e164. PMID: 12802782, DOI: 10.1086/374930.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisSymptomatic hyperlactatemiaLactic acidosisNormal serum lactate levelsHuman immunodeficiency virus (HIV) infectionNucleoside reverse transcriptase inhibitorSymptomatic lactic acidosisImmunodeficiency virus infectionSerum lactate levelsHuman immunodeficiency virusReverse transcriptase inhibitorAcute coinfectionAntiretroviral therapyHIV infectionHepatic insultImmunodeficiency virusAppropriate treatmentVirus infectionLactate levelsFirst presentationGranulocytic ehrlichiosisPatientsHyperlactatemiaAcidosisInfection